Intraocular delivery of crystalline sorafenib provides sustained, potent inhibition of wet age-related macular degeneration.

Saved in:
Bibliographic Details
Title: Intraocular delivery of crystalline sorafenib provides sustained, potent inhibition of wet age-related macular degeneration.
Authors: Lu H; Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Rakoski AI; Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Biomedical Engineering, Translational Tissue Engineering Center, Johns Hopkins School of Medicine, Baltimore, MD, USA., Ri K; Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Zhou L; Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Shi L; Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Cho H; Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Wu S; Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Chen SS; Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Biomedical Engineering, Translational Tissue Engineering Center, Johns Hopkins School of Medicine, Baltimore, MD, USA., Neill AN; Department of Chemistry, The Johns Hopkins University, Baltimore, MD, USA., Catazaro J; Department of Chemistry, The Johns Hopkins University, Baltimore, MD, USA., Wong VW; Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Biomedical Engineering, Translational Tissue Engineering Center, Johns Hopkins School of Medicine, Baltimore, MD, USA., Yoo A; Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Biomedical Engineering, Translational Tissue Engineering Center, Johns Hopkins School of Medicine, Baltimore, MD, USA., Wilson DS; Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Biomedical Engineering, Translational Tissue Engineering Center, Johns Hopkins School of Medicine, Baltimore, MD, USA., Doloff JC; Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Biomedical Engineering, Translational Tissue Engineering Center, Johns Hopkins School of Medicine, Baltimore, MD, USA; Department of Materials Science and Engineering, Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD, USA; Department of Oncology, Division of Cancer Immunology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Sidney-Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Bloomberg∼Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: jcdoloff@jhu.edu., Duh EJ; Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: eduh@jhmi.edu.
Source: Journal of controlled release : official journal of the Controlled Release Society [J Control Release] 2026 Jun 18; Vol. 397, pp. 115120. Date of Electronic Publication: 2026 Jun 18.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Science Publishers Country of Publication: Netherlands NLM ID: 8607908 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-4995 (Electronic) Linking ISSN: 01683659 NLM ISO Abbreviation: J Control Release Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1873-4995
DOI:10.1016/j.jconrel.2026.115120